Litcius/Paper detail

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hans Gelderblom, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Gabriel Tinoco, Kjetil Boye, Javier Martín‐Broto, Emanuela Palmerini, Salvatore Tafuto, Sarah Pratap, Benjamin Powers, Peter Reichardt, Antonio Casado, Piotr Rutkowski, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean‐Yves Blay, William D. Tap, Herbert H. Loong, Antonella Brunello, Andreas H. Krieg, Mark Algulnik, Richard F. Riedel, Scott H. Okuno, Elizabeth T. Loggers, Thierry Alcindor, Virginia Ferraresi, César Serrano, R. Lor Randall, Breelyn A. Wilky, Vinod Ravi

2024The Lancet67 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboClinical endpointPopulationSurgeryClinical trialInternal medicineAdverse effectPathologyAlternative medicineEnvironmental healthMusculoskeletal synovial abnormalities and treatmentsTendon Structure and TreatmentBone Tumor Diagnosis and Treatments
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Litcius